Deep vein thrombosis recurrent

Also known as: Recurrent deep venous thrombosis / Recurrent deep vein thrombosis / Recurrent DVT / DVT / Deep venous thrombosis NOS / DVT - not obstetric / Thrombosis venous deep / Deep vein thrombosis NOS / Deep vein thrombosis

DrugDrug NameDrug Description
DB06605ApixabanApixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043].
DB06695Dabigatran etexilateDabigatran etexilate is an oral prodrug that is hydrolyzed to the competitive and reversible direct thrombin inhibitor [dabigatran][Label,A177463,A6970]. Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom anticoagulation therapy is indicated[A177463]. In contrast to warfarin, because its anticoagulant effects are predictable, lab monitoring is not necessary[A177463]. Dabigatran etexilate was approved by the FDA in 2010[L6022].
DB06228RivaroxabanRivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011.
DrugDrug NamePhaseStatusCount